Skip to main content
. Author manuscript; available in PMC: 2020 Aug 4.
Published in final edited form as: Cancer Discov. 2019 Aug 21;9(11):1574–1589. doi: 10.1158/2159-8290.CD-18-1308

Figure 1: ADAMDEC1 is associated with malignancy in GBM.

Figure 1:

(A) Expression of ADAM family metalloproteinases across different GBM datasets. Expression levels were normalized to normal brain tissue samples and are presented as fold change. ADAMDEC1 is highly expressed across all datasets. (B) Kaplan-Meier survival analysis of TCGA data, stratified for above-median (high) or below-median (low) gene expression shows a significantly poorer survival in ADAMDEC1 high tumors. (C) ADAMDEC1 mRNA expression levels are significantly increased in GBM compared to lower grade gliomas (TCGA). (D) Immunohistochemistry demonstrates ADAMDEC1 expression in GBM. (E) Immunofluorescence shows ADAMDEC1 is absent in tumor-associated microglia (left and center panels; scale bars 50 µm), but is expressed in human xenografted GBM cells (far right panel; GBM cells identified by human-specific Nestin; scale bar 10 µm). Nuclei are counterstained with DAPI.